{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:29:11Z","timestamp":1793730551782,"version":"4.6.1"},"reference-count":146,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Am J Phys Med Rehabil"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Spinal muscular atrophy is a heterogeneous disease that results in loss of motor function. In an evolving treatment landscape, establishing the suitability and limitations of existing motor function scales and patient-reported outcomes used to monitor patients with this disease is important. A systematic review was conducted to examine utility of motor function scales and patient-reported outcomes in evaluating patients with spinal muscular atrophy. Published literature was reviewed up to June 2021 with no start date restriction. Of the reports screened, 122 were deemed appropriate for inclusion and are discussed in this review (including 24 validation studies for motor function scales or patient-reported outcomes). Fifteen motor function scales and patient-reported outcomes were identified to be commonly used (\u22655 studies), of which 11 had available validation assessments. Each instrument has its strengths and limitations. It is imperative that the patient population (e.g., age, mobility), goals of treatment, and outcomes or endpoints of interest be considered when selecting the appropriate motor function scales and patient-reported outcomes for clinical studies.<\/jats:p>","DOI":"10.1097\/phm.0000000000001869","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T15:46:28Z","timestamp":1630943188000},"page":"590-608","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":32,"title":["Systematic Review of Motor Function Scales and Patient-Reported Outcomes in Spinal Muscular Atrophy"],"prefix":"10.1097","volume":"101","author":[{"given":"Jennifer W.","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pepler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Maturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria C. F.","family":"Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Sarmiento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Haldenby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"bib1-20250616","doi-asserted-by":"crossref","first-page":"e33572","DOI":"10.1371\/journal.pone.0033572","article-title":"Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"bib2-20250616","first-page":"1348","article-title":"Spinal muscular atrophy","volume":"26","year":"2020","journal-title":"Continuum (Minneap Minn)"},{"key":"bib3-20250616","first-page":"7","article-title":"Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases","volume":"3","year":"2016","journal-title":"Front Mol Biosci"},{"key":"bib4-20250616","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1101\/gad.1884910","article-title":"A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity","volume":"24","year":"2010","journal-title":"Genes Dev"},{"key":"bib5-20250616","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.24497","article-title":"Spinal muscular atrophy: diagnosis and management in a new therapeutic era","volume":"51","year":"2015","journal-title":"Muscle Nerve"},{"key":"bib6-20250616","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","article-title":"209th ENMC International Workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7\u20139 November 2014, Heemskerk, the Netherlands","volume":"25","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"bib7-20250616","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.3390\/jcm9072222","article-title":"New treatments in spinal muscular atrophy: positive results and new challenges","volume":"9","year":"2020","journal-title":"J Clin Med"},{"key":"bib8-20250616","doi-asserted-by":"crossref","first-page":"e0230677","DOI":"10.1371\/journal.pone.0230677","article-title":"Diagnostic journey in spinal muscular atrophy: is it still an odyssey?","volume":"15","year":"2020","journal-title":"PLoS One"},{"key":"bib9-20250616","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14656566.2019.1704732","article-title":"New treatments in spinal muscular atrophy: an overview of currently available data","volume":"21","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"bib10-20250616","doi-asserted-by":"crossref","first-page":"2329048x211008725","DOI":"10.1177\/2329048X211008725","article-title":"Spinal muscular atrophy: the use of functional motor scales in the era of disease-modifying treatment","volume":"8","year":"2021","journal-title":"Child Neurol Open"},{"key":"bib11-20250616","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","year":"2020","journal-title":"Lancet Neurol"},{"key":"bib12-20250616","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","article-title":"Prospective cohort study of spinal muscular atrophy types 2 and 3","volume":"79","year":"2012","journal-title":"Neurology"},{"key":"bib13-20250616","doi-asserted-by":"crossref","first-page":"1756286421998902","DOI":"10.1177\/1756286421998902","article-title":"Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy","volume":"14","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"bib14-20250616","doi-asserted-by":"crossref","first-page":"92","DOI":"10.12968\/ijpn.2018.24.2.92","article-title":"Targeted palliative care day therapy interventions using modified MYMOP2 tool can improve outcomes for patients with non-malignant diseases","volume":"24","year":"2018","journal-title":"Int J Palliat Nurs"},{"key":"bib15-20250616","doi-asserted-by":"crossref","first-page":"68","DOI":"10.7224\/1537-2073.2013-021","article-title":"Treatment satisfaction in multiple sclerosis","volume":"16","year":"2014","journal-title":"Int J MS Care"},{"key":"bib16-20250616","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred Reporting items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement","volume":"4","year":"2015","journal-title":"Syst Rev"},{"key":"bib17-20250616","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.nmd.2005.07.005","article-title":"134th ENMC International Workshop: outcome measures and treatment of spinal muscular atrophy, 11\u201313 February 2005, Naarden, the Netherlands","volume":"15","year":"2005","journal-title":"Neuromuscul Disord"},{"key":"bib18-20250616","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.nmd.2019.10.001","article-title":"A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy","volume":"29","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"bib20-20250616","doi-asserted-by":"crossref","first-page":"2794036","DOI":"10.1155\/2020\/2794036","article-title":"Minimum clinically important difference of gross motor function and gait endurance in children with motor impairment: a comparison of distribution-based approaches","volume":"2020","year":"2020","journal-title":"Biomed Res Int"},{"key":"bib21-20250616","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","article-title":"Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy","volume":"17","year":"2017","journal-title":"BMC Neurol"},{"key":"bib22-20250616","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12883-017-0853-y","article-title":"A qualitative study of perceptions of meaningful change in spinal muscular atrophy","volume":"17","year":"2017","journal-title":"BMC Neurol"},{"key":"bib23-20250616","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1111\/ene.14472","article-title":"Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy","volume":"27","year":"2020","journal-title":"Eur J Neurol"},{"key":"bib24-20250616","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.nmd.2014.11.008","article-title":"Upper limb module in non-ambulant patients with spinal muscular atrophy: 12 month changes","volume":"25","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"bib25-20250616","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mus.26419","article-title":"Revised Upper Limb Module for spinal muscular atrophy: 12 month changes","volume":"59","year":"2019","journal-title":"Muscle Nerve"},{"key":"bib26-20250616","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1367\/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2","article-title":"The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity","volume":"3","year":"2003","journal-title":"Ambul Pediatr"},{"key":"bib27-20250616","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s100670050065","article-title":"Application of statistical graphics to facilitate selection of health status measures for clinical practice and evaluative research","volume":"18","year":"1999","journal-title":"Clin Rheumatol"},{"key":"bib28-20250616","first-page":"l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","year":"2019","journal-title":"BMJ"},{"key":"bib29-20250616","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejpn.2020.05.002","article-title":"Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: real world data from Hungarian patients","volume":"27","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"bib30-20250616","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/dmcn.14412","article-title":"Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen","volume":"62","year":"2020","journal-title":"Dev Med Child Neurol"},{"key":"bib31-20250616","first-page":"e1312","article-title":"Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: a cohort study","volume":"91","year":"2018","journal-title":"Neurology"},{"key":"bib32-20250616","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","article-title":"Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study","volume":"15","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"bib33-20250616","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/mus.26633","article-title":"Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy","volume":"60","year":"2019","journal-title":"Muscle Nerve"},{"key":"bib34-20250616","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study","volume":"29","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"bib35-20250616","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"bib36-20250616","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib37-20250616","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.braindev.2020.07.014","article-title":"Administration of nusinersen via paramedian approach for spinal muscular atrophy","volume":"43","year":"2021","journal-title":"Brain Dev"},{"key":"bib38-20250616","doi-asserted-by":"crossref","first-page":"e0165818","DOI":"10.1371\/journal.pone.0165818","article-title":"Spontaneous breathing pattern as respiratory functional outcome in children with spinal muscular atrophy (SMA)","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"bib39-20250616","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ana.25533","article-title":"Nusinersen in type 1 spinal muscular atrophy: twelve-month real-world data","volume":"86","year":"2019","journal-title":"Ann Neurol"},{"key":"bib40-20250616","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3233\/JND-180315","article-title":"Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in germany","volume":"5","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"bib41-20250616","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JND-190403","article-title":"AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort","volume":"6","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"bib42-20250616","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nmd.2017.09.015","article-title":"Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy","volume":"28","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"bib43-20250616","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","year":"2014","journal-title":"Neurology"},{"key":"bib44-20250616","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/acn3.283","article-title":"Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study","volume":"3","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"bib45-20250616","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","year":"2017","journal-title":"Ann Neurol"},{"key":"bib46-20250616","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","article-title":"Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy","volume":"98","year":"2019","journal-title":"Pediatr Neurol"},{"key":"bib47-20250616","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib48-20250616","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","article-title":"NFL is a marker of treatment response in children with SMA treated with nusinersen","volume":"266","year":"2019","journal-title":"J Neurol"},{"key":"bib49-20250616","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.nmd.2018.05.010","article-title":"Nusinersen in type 1 SMA infants, children and young adults: preliminary results on motor function","volume":"28","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"bib50-20250616","doi-asserted-by":"crossref","first-page":"e0199657","DOI":"10.1371\/journal.pone.0199657","article-title":"Ambulatory function in spinal muscular atrophy: age-related patterns of progression","volume":"13","year":"2018","journal-title":"PLoS One"},{"key":"bib51-20250616","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1097\/BPO.0000000000001247","article-title":"Preliminary safety and tolerability of a novel subcutaneous intrathecal catheter system for repeated outpatient dosing of nusinersen to children and adults with spinal muscular atrophy","volume":"38","year":"2018","journal-title":"J Pediatr Orthop"},{"key":"bib52-20250616","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JND-190465","article-title":"Feeding and swallowing problems in infants with spinal muscular atrophy type 1: an observational study","volume":"7","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"bib53-20250616","first-page":"e696","article-title":"An observational study of functional abilities in infants, children, and adults with type 1 SMA","volume":"91","year":"2018","journal-title":"Neurology"},{"key":"bib54-20250616","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5603\/PJNNS.a2021.0020","article-title":"Nusinersen treatment of spinal muscular atrophy type 1\u2014results of expanded access programme in Poland","volume":"55","year":"2021","journal-title":"Neurol Neurochir Pol"},{"key":"bib55-20250616","first-page":"e1988","article-title":"Muscle strength and motor function in adolescents and adults with spinal muscular atrophy","volume":"95","year":"2020","journal-title":"Neurology"},{"key":"bib56-20250616","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1212\/WNL.0b013e3182020332","article-title":"Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy","volume":"75","year":"2010","journal-title":"Neurology"},{"key":"bib57-20250616","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archneurol.2010.373","article-title":"Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year","volume":"68","year":"2011","journal-title":"Arch Neurol"},{"key":"bib58-20250616","doi-asserted-by":"crossref","first-page":"2329048X18780477","DOI":"10.1177\/2329048X18780477","article-title":"Vibration-assisted home training program for children with spinal muscular atrophy","volume":"5","year":"2018","journal-title":"Child Neurol Open"},{"key":"bib59-20250616","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/PHM.0b013e318269d66b","article-title":"Correlations between change scores of measures for muscle strength and motor function in individuals with spinal muscular atrophy types 2 and 3","volume":"92","year":"2013","journal-title":"Am J Phys Med Rehabil"},{"key":"bib60-20250616","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/ene.13534","article-title":"Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4","volume":"25","year":"2018","journal-title":"Eur J Neurol"},{"key":"bib61-20250616","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(17)30085-6","article-title":"Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","year":"2017","journal-title":"Lancet Neurol"},{"key":"bib62-20250616","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2377-11-36","article-title":"Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid","volume":"11","year":"2011","journal-title":"BMC Neurol"},{"key":"bib63-20250616","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.nmd.2014.01.003","article-title":"Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients","volume":"24","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"bib64-20250616","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nmd.2003.11.006","article-title":"Pilot trial of phenylbutyrate in spinal muscular atrophy","volume":"14","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"bib65-20250616","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.nmd.2009.11.008","article-title":"Physical characteristics and applicability of standard assessment methods in a total population of spinal muscular atrophy type II patients","volume":"20","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"bib66-20250616","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/01.wnl.0000249142.82285.d6","article-title":"Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy","volume":"68","year":"2007","journal-title":"Neurology"},{"key":"bib67-20250616","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.nmd.2007.02.006","article-title":"The Hammersmith Functional Score correlates with the SMN2 copy number: a multicentric study","volume":"17","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"bib68-20250616","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.nmd.2008.05.004","article-title":"Daily salbutamol in young patients with SMA type II","volume":"18","year":"2008","journal-title":"Neuromuscul Disord"},{"key":"bib69-20250616","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jpeds.2012.05.067","article-title":"Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy","volume":"162","year":"2013","journal-title":"J Pediatr"},{"key":"bib70-20250616","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/mus.25148","article-title":"Correlates of health related quality of life in adult patients with spinal muscular atrophy","volume":"54","year":"2016","journal-title":"Muscle Nerve"},{"key":"bib71-20250616","first-page":"e2492","article-title":"Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies","volume":"92","year":"2019","journal-title":"Neurology"},{"key":"bib72-20250616","first-page":"109","article-title":"Perceived fatigue in spinal muscular atrophy: a pilot study","volume":"6","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"bib73-20250616","doi-asserted-by":"crossref","first-page":"1756286418803246","DOI":"10.1177\/1756286418803246","article-title":"Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy","volume":"11","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"bib74-20250616","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nmd.2013.10.011","article-title":"Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study","volume":"24","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"bib75-20250616","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","year":"2016","journal-title":"Neurology"},{"key":"bib76-20250616","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.21838","article-title":"Compound muscle action potential and motor function in children with spinal muscular atrophy","volume":"42","year":"2010","journal-title":"Muscle Nerve"},{"key":"bib77-20250616","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1007\/s00415-020-09847-8","article-title":"Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy","volume":"267","year":"2020","journal-title":"J Neurol"},{"key":"bib78-20250616","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.nmd.2010.05.013","article-title":"Adiposity is increased among high-functioning, non-ambulatory patients with spinal muscular atrophy","volume":"20","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"bib79-20250616","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/mus.24748","article-title":"Old measures and new scores in spinal muscular atrophy patients","volume":"52","year":"2015","journal-title":"Muscle Nerve"},{"key":"bib80-20250616","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.sleep.2016.11.012","article-title":"Sleep disorders in spinal muscular atrophy","volume":"30","year":"2017","journal-title":"Sleep Med"},{"key":"bib81-20250616","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/PEP.0000000000000515","article-title":"Quantitative evaluation of lower extremity joint contractures in spinal muscular atrophy: implications for motor function","volume":"30","year":"2018","journal-title":"Pediatr Phys Ther"},{"key":"bib82-20250616","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1177\/0883073811405053","article-title":"Thigh muscle volume measured by magnetic resonance imaging is stable over a 6-month interval in spinal muscular atrophy","volume":"26","year":"2011","journal-title":"J Child Neurol"},{"key":"bib83-20250616","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/mus.26909","article-title":"Motor unit number index in children with later-onset spinal muscular atrophy","volume":"62","year":"2020","journal-title":"Muscle Nerve"},{"key":"bib84-20250616","doi-asserted-by":"crossref","first-page":"1756286419846058","DOI":"10.1177\/1756286419846058","article-title":"Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment","volume":"12","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"bib85-20250616","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/biomedicines8020021","article-title":"Circulating MyomiRs as potential biomarkers to monitor response to nusinersen in pediatric SMA patients","volume":"8","year":"2020","journal-title":"Biomedicines"},{"key":"bib86-20250616","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/JND-190462","article-title":"Scoliosis surgery significantly impacts motor abilities in higher-functioning individuals with spinal muscular atrophy1","volume":"7","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"bib87-20250616","doi-asserted-by":"crossref","first-page":"e4357","DOI":"10.1002\/nbm.4357","article-title":"Quantitative MRI of skeletal muscle in a cross-sectional cohort of patients with spinal muscular atrophy types 2 and 3","volume":"33","year":"2020","journal-title":"NMR Biomed"},{"key":"bib88-20250616","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.nmd.2020.07.004","article-title":"Gain and loss of abilities in type II SMA: a 12-month natural history study","volume":"30","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"bib89-20250616","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.nmd.2020.07.005","article-title":"Age and baseline values predict 12 and 24-month functional changes in type 2 SMA","volume":"30","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"bib90-20250616","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","article-title":"Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3","volume":"91","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"bib91-20250616","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s13311-020-01004-3","article-title":"Reldesemtiv in patients with spinal muscular atrophy: a phase 2 hypothesis-generating study","volume":"18","year":"2021","journal-title":"Neurotherapeutics"},{"key":"bib92-20250616","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3233\/JND-190453","article-title":"Prospective cohort study of nusinersen treatment in adults with spinal muscular atrophy","volume":"7","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"bib93-20250616","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1111\/jcmm.14939","article-title":"Nusinersen treatment and cerebrospinal fluid neurofilaments: an explorative study on spinal muscular atrophy type 3 patients","volume":"24","year":"2020","journal-title":"J Cell Mol Med"},{"key":"bib94-20250616","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/mus.24081","article-title":"Leg muscle function and fatigue during walking in spinal muscular atrophy type 3","volume":"50","year":"2014","journal-title":"Muscle Nerve"},{"key":"bib95-20250616","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3\u2014a prospective observational study","volume":"6","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"bib96-20250616","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/ana.25900","article-title":"Clinical variability in spinal muscular atrophy type III","volume":"88","year":"2020","journal-title":"Ann Neurol"},{"key":"bib97-20250616","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib98-20250616","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.nmd.2016.10.002","article-title":"Developmental milestones in type I spinal muscular atrophy","volume":"26","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"bib99-20250616","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/ppul.25142","article-title":"Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen","volume":"56","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"bib100-20250616","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study","volume":"63","year":"2021","journal-title":"Muscle Nerve"},{"key":"bib101-20250616","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.apmr.2013.01.014","article-title":"Responsiveness of the motor function measure in patients with spinal muscular atrophy","volume":"94","year":"2013","journal-title":"Arch Phys Med Rehabil"},{"key":"bib102-20250616","doi-asserted-by":"crossref","first-page":"e0201004","DOI":"10.1371\/journal.pone.0201004","article-title":"Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study","volume":"13","year":"2018","journal-title":"PLoS One"},{"key":"bib103-20250616","doi-asserted-by":"crossref","first-page":"e0121799","DOI":"10.1371\/journal.pone.0121799","article-title":"Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"bib104-20250616","doi-asserted-by":"crossref","first-page":"e35462","DOI":"10.1371\/journal.pone.0035462","article-title":"Candidate proteins, metabolites and transcripts in the biomarkers for spinal muscular atrophy (BforSMA) clinical study","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"bib105-20250616","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejpn.2010.07.003","article-title":"Self-reported quality of life has no correlation with functional status in children and adolescents with spinal muscular atrophy","volume":"15","year":"2011","journal-title":"Eur J Paediatr Neurol"},{"key":"bib106-20250616","doi-asserted-by":"crossref","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","article-title":"SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of l-carnitine and valproic acid in spinal muscular atrophy","volume":"5","year":"2010","journal-title":"PLoS One"},{"key":"bib107-20250616","doi-asserted-by":"crossref","first-page":"e5268","DOI":"10.1371\/journal.pone.0005268","article-title":"Phase II open label study of valproic acid in spinal muscular atrophy","volume":"4","year":"2009","journal-title":"PLoS One"},{"key":"bib108-20250616","doi-asserted-by":"crossref","first-page":"11069","DOI":"10.1038\/s41598-020-68051-w","article-title":"Fatigue in adults with spinal muscular atrophy under treatment with nusinersen","volume":"10","year":"2020","journal-title":"Sci Rep"},{"key":"bib109-20250616","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3233\/JND-150101","article-title":"Single-blind, randomized, controlled clinical trial of exercise in ambulatory spinal muscular atrophy: why are the results negative?","volume":"2","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"bib110-20250616","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/mus.26756","article-title":"Outcome measures in a cohort of ambulatory adults with spinal muscular atrophy","volume":"61","year":"2020","journal-title":"Muscle Nerve"},{"key":"bib111-20250616","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jmedgenet-2018-105482","article-title":"Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol","volume":"56","year":"2019","journal-title":"J Med Genet"},{"key":"bib112-20250616","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/ejhg.2012.233","article-title":"Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study","volume":"21","year":"2013","journal-title":"Eur J Hum Genet"},{"key":"bib113-20250616","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.nmd.2013.06.001","article-title":"Six minute walk test in type III spinal muscular atrophy: a 12 month longitudinal study","volume":"23","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"bib114-20250616","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/0883073813493663","article-title":"Weakness and fatigue in diverse neuromuscular diseases","volume":"28","year":"2013","journal-title":"J Child Neurol"},{"key":"bib115-20250616","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/08830738030180080501","article-title":"Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study","volume":"18","year":"2003","journal-title":"J Child Neurol"},{"key":"bib116-20250616","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/mus.20018","article-title":"Motor function-muscle strength relationship in spinal muscular atrophy","volume":"29","year":"2004","journal-title":"Muscle Nerve"},{"key":"bib117-20250616","doi-asserted-by":"crossref","first-page":"e21296","DOI":"10.1371\/journal.pone.0021296","article-title":"SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of l-carnitine and valproic acid in ambulatory children with spinal muscular atrophy","volume":"6","year":"2011","journal-title":"PLoS One"},{"key":"bib118-20250616","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejpn.2013.09.005","article-title":"Whole-body vibration training in children with Duchenne muscular dystrophy and spinal muscular atrophy","volume":"18","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"key":"bib119-20250616","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.pediatrneurol.2014.01.037","article-title":"Health-related quality of life in children and adolescents with spinal muscular atrophy in the Czech Republic","volume":"50","year":"2014","journal-title":"Pediatr Neurol"},{"issue":"pt 11","key":"bib120-20250616","first-page":"3185","article-title":"Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy","volume":"134","year":"2011","journal-title":"Brain"},{"issue":"1\u20132","key":"bib121-20250616","first-page":"127","article-title":"A placebo-controlled trial of gabapentin in spinal muscular atrophy","volume":"191","year":"2001","journal-title":"J Neurol Sci"},{"key":"bib122-20250616","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.clinph.2018.08.025","article-title":"The motor unit number index (MUNIX) profile of patients with adult spinal muscular atrophy","volume":"129","year":"2018","journal-title":"Clin Neurophysiol"},{"key":"bib123-20250616","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability","volume":"20","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"bib124-20250616","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/PEP.0b013e3182351f04","article-title":"Validation of the Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)","volume":"23","year":"2011","journal-title":"Pediatr Phys Ther"},{"key":"bib125-20250616","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/mus.23937","article-title":"Rasch analysis of clinical outcome measures in spinal muscular atrophy","volume":"49","year":"2014","journal-title":"Muscle Nerve"},{"key":"bib126-20250616","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneur.59.9.1445","article-title":"Outcome measures for pediatric spinal muscular atrophy","volume":"59","year":"2002","journal-title":"Arch Neurol"},{"key":"bib127-20250616","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/archneur.60.8.1130","article-title":"Reliability of 4 outcome measures in pediatric spinal muscular atrophy","volume":"60","year":"2003","journal-title":"Arch Neurol"},{"key":"bib128-20250616","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.nmd.2006.03.005","article-title":"The Gross Motor Function Measure is a valid and sensitive outcome measure for spinal muscular atrophy","volume":"16","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"bib129-20250616","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1090-3798(03)00060-6","article-title":"The Hammersmith Functional Motor Scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation","volume":"7","year":"2003","journal-title":"Eur J Paediatr Neurol"},{"key":"bib130-20250616","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nmd.2005.11.010","article-title":"Reliability of the Hammersmith Functional Motor Scale for spinal muscular atrophy in a multicentric study","volume":"16","year":"2006","journal-title":"Neuromuscul Disord"},{"issue":"9\u201310","key":"bib131-20250616","first-page":"693","article-title":"An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients","volume":"17","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"bib132-20250616","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1177\/0883073811420294","article-title":"Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III","volume":"26","year":"2011","journal-title":"J Child Neurol"},{"key":"bib133-20250616","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.nmd.2006.03.015","article-title":"A modified Hammersmith Functional Motor Scale for use in multi-center research on spinal muscular atrophy","volume":"16","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"bib134-20250616","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/mus.22040","article-title":"Reliability of the modified Hammersmith Functional Motor Scale in young children with spinal muscular atrophy","volume":"44","year":"2011","journal-title":"Muscle Nerve"},{"key":"bib135-20250616","doi-asserted-by":"crossref","first-page":"e0172346","DOI":"10.1371\/journal.pone.0172346","article-title":"Revised Hammersmith Scale for spinal muscular atrophy: a SMA specific clinical outcome assessment tool","volume":"12","year":"2017","journal-title":"PLoS One"},{"key":"bib136-20250616","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.apmr.2013.04.001","article-title":"Motor function measure: validation of a short form for young children with neuromuscular diseases","volume":"94","year":"2013","journal-title":"Arch Phys Med Rehabil"},{"key":"bib137-20250616","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nmd.2005.03.004","article-title":"A motor function measure for neuromuscular diseases. Construction and validation study","volume":"15","year":"2005","journal-title":"Neuromuscul Disord"},{"key":"bib138-20250616","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40120-020-00206-3","article-title":"Validity and reliability of the 32-item Motor Function Measure in 2- to 5-year-olds with neuromuscular disorders and 2- to 25-year-olds with spinal muscular atrophy","volume":"9","year":"2020","journal-title":"Neurol Ther"},{"key":"bib139-20250616","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3109\/09638288.2014.892157","article-title":"The applicability of four clinical methods to evaluate arm and hand function in all stages of spinal muscular atrophy type II","volume":"36","year":"2014","journal-title":"Disabil Rehabil"},{"key":"bib140-20250616","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"Revised Upper Limb Module for spinal muscular atrophy: development of a new module","volume":"55","year":"2017","journal-title":"Muscle Nerve"},{"key":"bib141-20250616","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.nmd.2011.02.014","article-title":"Assessing upper limb function in nonambulant SMA patients: development of a new module","volume":"21","year":"2011","journal-title":"Neuromuscul Disord"},{"key":"bib142-20250616","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1212\/WNL.0b013e3181d3e308","article-title":"Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy","volume":"74","year":"2010","journal-title":"Neurology"},{"key":"bib143-20250616","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.nmd.2009.09.009","article-title":"The PedsQL in pediatric patients with spinal muscular atrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory generic core scales and neuromuscular module","volume":"19","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"bib144-20250616","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.nmd.2009.12.002","article-title":"Reliability of telephone administration of the PedsQL Generic Quality of Life Inventory and Neuromuscular Module in spinal muscular atrophy (SMA)","volume":"20","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"2 pt 1","key":"bib145-20250616","first-page":"153","article-title":"Optimality score for the neurologic examination of the infant at 12 and 18 months of age","volume":"135","year":"1999","journal-title":"J Pediatr"},{"key":"bib148-20250616","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials","volume":"26","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"bib149-20250616","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","year":"2021","journal-title":"New Engl J Med"}],"container-title":["American Journal of Physical Medicine &amp; Rehabilitation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PHM.0000000000001869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T17:10:13Z","timestamp":1750093813000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PHM.0000000000001869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":146,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/phm.0000000000001869","relation":{},"ISSN":["1537-7385","0894-9115"],"issn-type":[{"value":"1537-7385","type":"electronic"},{"value":"0894-9115","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,3]]}}}